To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Clinical trial NCT04052971 · COMPLETED
Trial details
- NCT number
- NCT04052971
- Sponsor
- Abion Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-01
- Primary completion
- 2023-11-30
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.